Revolutionary Liquid Adult Anti-Inflammatory Vanapain Rebranded As TexaClear

Published: Nov 02, 2016

ARLINGTON, Texas, Nov. 2, 2016 /PRNewswire/ -- The H-E-B exclusive brand TexaClear® announces today their expansion into liquid pain relief with the acquired formulas formerly known as VanaPain®, now re-branded as TexaClear® Pain Reliever. The new branding is complemented by a new and improved taste while still providing the same fast acting, liquid relief for both daytime and nighttime pains.

TexaClear® Pain Relievers are a pill-free solution to bring more consumers liquid-fast relief from headaches, backaches, muscle aches, minor arthritis pain, and menstrual cramps among others. Both formulas contain the non-steroidal anti-inflammatory drug (NSAID), Choline Salicylate, which effectively relieves pain and reduces inflammation associated with pain. The revolutionary daytime formula is combined with the pain reliever aid caffeine, while the nighttime formula is combined with a non-habit forming sleep aid for a restful night's sleep.

TexaClear® Pain Relievers and all the other fine TexaClear® products are sold exclusively at H-E-B Stores. For more information,

About TexaClear - Just clear, powerful, effective relief, exclusively for Texans

In 2014, GM Pharmaceuticals, Inc. partnered with H-E-B to bring a full line of clear and powerful over-the-counter medications to the market. TexaClear® was inspired by the Texas-roots of both companies, and their shared vision of bringing innovation to the over-the-counter drug market. The TexaClear® brand now consists of over a dozen multi-symptom relief formulas that deliver liquid fast relief without the use of dyes, gluten, sugar, alcohol, acetaminophen or even artificial flavors.

About GM Pharmaceuticals

GM Pharmaceuticals, Inc. is a Texas-based pharmaceutical company that has developed and marketed prescription and over-the-counter medications for over 25 years.

This content was issued through the press release distribution service at For more info visit:

To view the original version on PR Newswire, visit:

SOURCE TexaClear(R)

Back to news